Thermo Fisher Scientific reports Q1 2026 results on May 20 carrying the weight of a brutal month — down 17% — and a sell-side that has been quietly but consistently trimming its price targets.
The analyst story here is not about rating cuts — the conviction ratings held firm. But the direction of travel has been one-way. Multiple firms lowered targets in April and early May: Wells Fargo cut to $615 from $675, Stifel to $600 from $700, Baird to $639 from $653, and Barclays to $625 from $650. Every recent move has been a reduction. The consensus still sits at "hold" with a mean target of $612, implying roughly 40% upside from Friday's close of $438. That gap is large enough to invite scrutiny — bulls argue Thermo Fisher's life science solutions segment is positioned for a multi-year compounding cycle, with projected EPS growing at an 8.5% compound annual rate, while the Clario acquisition deepens its CRO franchise as biopharma outsourcing trends accelerate. Bears counter with margin compression: adjusted EBIT margins fell around 830 basis points between 2021 and 2024, and biotech funding — a key demand driver — started 2025 slowly. The 17x trailing PE and 15.5x EV/EBITDA are not demanding, but they assume a margin recovery that has yet to materialise.
The options market has taken on a slightly more constructive tilt into the print. The put/call ratio of 1.23 runs fractionally below its 20-day average of 1.28 — a z-score of -1.5 — suggesting options traders are not adding fresh downside hedges despite the share price weakness. That is a modest divergence from the bearish price action, worth noting. The RSI sits at 33, deep in oversold territory, adding technical context to how stretched the drawdown has become.
Short interest barely registers as a meaningful force here. At 1.3% of free float — up 30% over the past month in share terms — the increase is notable in pace but not in scale. Borrow availability is exceptionally loose, and the cost to borrow runs near 0.43%, reflecting no meaningful demand for shorts in the lending market. The short score of 30 is modest. This is not a short-driven story.
Peers tell a broadly similar tale of sector pain. DHR fell about 5% on the week, RGEN dropped nearly 17%, and CRL shed 15%. TMO's weekly decline of 5.7% is relatively contained against that backdrop, suggesting the stock absorbed some of the sector pressure earlier and in larger doses. The last confirmed earnings event on April 23 produced a one-day drop of 8.6% and a five-day decline of 6.8% — the previous event in late January saw a 11% one-day fall. The pattern of heavy post-print selling is now well-established.
The May 20 print is therefore less about whether Thermo Fisher can sustain its strategic narrative and more about whether management can show the margin trajectory has stopped deteriorating — at a price level that has already priced in considerable doubt.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
